| rs3897708 |
chr11 |
89062444 |
0.0000157 |
C |
T |
Antineutrophil cytoplasmic antibody-associated vasculitis |
NOX4 |
intron |
22808956
|
| rs3897708 |
chr11 |
89062444 |
0.000526 |
C |
T |
Smoking initiation |
NOX4 |
intron |
24665060
|
| rs1847138 |
chr11 |
89094606 |
1.32e-30 |
T |
C |
Narcolepsy |
NOX4 |
intron |
19629137
|
| rs7944576 |
chr11 |
89099263 |
0.000107 |
C |
T |
Prostate cancer |
NOX4 |
intron |
23023329
|
| rs10830264 |
chr11 |
89111382 |
0.000035 |
T |
G |
Cholesterol |
NOX4 |
intron |
17255346
|
| rs10830265 |
chr11 |
89112650 |
0.000008 |
G |
A |
Obesity-related traits |
NOX4 |
intron |
23251661
|
| rs317150 |
chr11 |
89123768 |
0.00000847 |
C |
T |
Obesity-related traits |
NOX4 |
intron |
23251661
|
| rs12574346 |
chr11 |
89139213 |
0.0000389 |
C |
A |
Cognitive impairment induced by topiramate |
NOX4 |
intron |
22091778
|
| rs1827432 |
chr11 |
89140368 |
0.0000794 |
T |
C |
Cholesterol |
NOX4 |
intron |
17255346
|
| rs7130284 |
chr11 |
89148372 |
2e-20 |
C |
T |
Homocysteine levels |
NOX4 |
intron |
23824729
|
| rs317148 |
chr11 |
89170515 |
0.00067 |
T |
C |
Type 2 diabetes and 6 quantitative traits |
NOX4 |
intron |
17848626
|
| rs2164522 |
chr11 |
89190489 |
0.0000656 |
G |
A |
Cholesterol |
NOX4 |
intron |
17255346
|
| rs11018622 |
chr11 |
89197483 |
0.000285 |
C |
T |
Taste perception |
NOX4 |
intron |
22132133
|
| rs957140 |
chr11 |
89201627 |
0.00000002 |
G |
A |
Homocysteine levels |
NOX4 |
intron |
23824729
|
| rs11018625 |
chr11 |
89202569 |
0.0000721 |
G |
A |
Cholesterol |
NOX4 |
intron |
17255346
|
| rs11018625 |
chr11 |
89202569 |
0.000623 |
G |
A |
Multiple complex diseases |
NOX4 |
intron |
17554300
|
| rs11018629 |
chr11 |
89206964 |
0.0000426 |
G |
A |
Cholesterol |
NOX4 |
intron |
17255346
|
| rs11018629 |
chr11 |
89206964 |
0.000235 |
G |
A |
Multiple complex diseases |
NOX4 |
intron |
17554300
|
| rs10830277 |
chr11 |
89208854 |
0.000346 |
T |
C |
Obesity (extreme) |
NOX4 |
intron |
21935397
|
| rs2164521 |
chr11 |
89209985 |
0.00023 |
G |
A |
Myocardial infarction |
NOX4 |
intron |
21107343
|
| rs497279 |
chr11 |
89217708 |
0.0000342 |
T |
C |
Type 2 diabetes |
NOX4 |
intron |
17463246
|
| rs514981 |
chr11 |
89221089 |
0.00091 |
C |
T |
Response to cytadine analogues (cytosine arabinoside) |
NOX4 |
intron |
24483146
|
| rs11600313 |
chr11 |
89237846 |
0.000566 |
T |
C |
Type 2 diabetes |
NOX4 |
intron |
17463246
|
| rs319024 |
chr11 |
89239875 |
0.000378 |
G |
A |
Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) |
NOX4 |
intron |
24023788
|
| rs11018639 |
chr11 |
89249939 |
0.0000945 |
G |
T |
Serum metabolites |
NOX4 |
intron |
19043545
|
| rs2917539 |
chr11 |
89253253 |
0.000849 |
C |
G |
Response to cytadine analogues (cytosine arabinoside) |
NOX4 |
intron |
24483146
|
| rs11018644 |
chr11 |
89261530 |
0.0000000000958 |
G |
T |
Metabolite levels |
NOX4 |
intron |
22286219
|
| rs3017883 |
chr11 |
89275712 |
0.00045 |
C |
A |
Response to cytidine analogues (gemcitabine) |
NOX4 |
intron |
24483146
|
| rs3017883 |
chr11 |
89275712 |
0.000586 |
C |
A |
Response to cytadine analogues (cytosine arabinoside) |
NOX4 |
intron |
24483146
|
| rs12293379 |
chr11 |
89276166 |
0.000494 |
T |
C |
Type 2 diabetes |
NOX4 |
intron |
17463246
|
| rs2917538 |
chr11 |
89281774 |
0.000659 |
G |
T |
Response to cytidine analogues (gemcitabine) |
NOX4 |
intron |
24483146
|
| rs3019011 |
chr11 |
89296364 |
0.00000628 |
A |
G |
Telomere length |
NOX4 |
intron |
23001564
|